HYFT MindWalk Therapeutics: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Despite a talent shortage and the competition for rare biochemist-programmers, MindWalk Holdings (HYFT) continues to grow steadily. This chart on GURU.Markets shows an EV/EBITDA of 0.00. The business relies on a SaaS model for biodata analysis, which ensures high margins. The application of AI in drug development eliminates physical research costs, optimizing therapeutic supply chains.

For a defensive portfolio, accounting for Enterprise Value (EV) relative to EBITDA is critical, as it allows for an assessment of the real value of assets amid changing borrowing costs. Given the volatile revenues of MindWalk Holdings (HYFT) and the absence of stable cash flow, the EV/EBITDA multiple for this capital-intensive business reveals a risk of equity overvaluation relative to its current ability to act as a cash generator.